Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets
---- Acknowledgments ----
Earlier versions of this paper were presented at the 2010 American Society of Health Economics meetings and the 2009 Harvard Law School conference on Legal and Regulatory Issues in Pharmaceutical Research and Development. This research was supported in part by the Merck Foundation Program on Pharmaceutical Policy Issues to the University of Pennsylvania. The analysis is based on data obtained under license from the IMS Health Incorporated MIDAS™ database. We would like to thank IMS Health and Pfizer Inc. for making the data available. The opinions expressed are those of the authors and do not necessarily reflect the opinions of the research sponsors, IMS Health or the National Bureau of Economic Research. We are responsible for all conclusions and any errors.